Drug Profile
CCP 08
Alternative Names: CCP-08Latest Information Update: 24 Mar 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Developer Tris Pharma
- Class Antitussives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Common cold; Cough
Most Recent Events
- 22 Mar 2021 Neos Therapeutics has been merged with Aytu BioScience to form Aytu Biopharma
- 15 Mar 2019 No recent reports of development identified for preregistration for Common cold in USA (PO)
- 15 Mar 2019 No recent reports of development identified for preregistration for Cough in USA (PO)